Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients

Reuters02-02 21:05

Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients

Guardant Health Inc. has announced the publication of results from the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202593149) on February 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608861677?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608861677","market":"us","top_or_hot":-1,"title":"Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> has announced the publication of results from the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202593149) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-02 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GH\">Guardant Health Inc.</a> has announced the publication of results from the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202593149) on February 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDLbjsR0l:1","article_id":"2608861677","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608861677","pubTimestamp":1770037519,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guardant Health Inc. has announced the publication of results from the largest study to date evaluating circulating tumor DNA  for molecular residual disease  detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","GH":"Guardant Health Inc.","BK4551":"寇图资本持仓","BK4588":"碎股","BK4196":"保健护理服务","BK4585":"ETF&股票定投概念"},"translate_title":"Guardant Reveal血液检测可改善III期结肠癌患者的复发预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":0.9},"content_text":"Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients\n    \n\nGuardant Health Inc. has announced the publication of results from the largest study to date evaluating circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260202593149) on February 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608861677","isCrawlerRequest":true}